Pharmaceuticals
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...
2023-09-13 20:29
2892
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets
SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...
2023-09-13 10:30
3519
Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration
CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ --
Pierre Fabre Laboratories
2023-09-12 20:00
2084
IPMG Drives Health Transformation and Strengthens Indonesia's Economy Through Efforts to Accelerate Access to Innovative Medicines and Vaccines, also Partnerships
JAKARTA, Indonesia, Sept. 11, 2023 /PRNewswire/ -- The research and development-based multinational pharmaceutical industry association, the International Pharmaceutical Manufacturers Group (IPMG) is always committed to supporting and encouraging advocacy and transformation of Government policie...
2023-09-11 18:52
2683
Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer
AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...
2023-09-11 15:00
1815
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors
SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "Biosyngen") announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial ofBRL03 for the treatment of lung cancer, gastric cancer and other ad...
2023-09-11 14:53
1955
Nobel Trust Family Joins BIOHK2023 - Unveiling Key Announcement
HONG KONG, Sept. 8, 2023 /PRNewswire/ -- BIOHK2023 garnered widespread acclaim featuring an exceptional lineup of speakers, including aNobel Laureate, world-renowned scientists who have won distinguished awards, and accomplished biotech C-level venture capitalists taking the stage on 13th to 16th...
2023-09-08 16:30
2775
SIFI TO PRESENT NEW SCIENTIFIC DATA DURING THE 41ST CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS
CATANIA, Italy, Sept. 8, 2023 /PRNewswire/ -- SIFI, a leading international ophthalmic company, is pleased to announce the presentation of new scientific data on its products during the upcomingCongress of The European Society of Cataract and Refractive Surgeons (ESCRS) which will take place from...
2023-09-08 14:00
2813
Adagene to Present at Investor and Scientific Conferences in September
- Adagene's CEO and President of R&D, Dr. Peter Luo, participating in SITC webinar onSeptember 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies - SAN DIEGO and SUZHOU, China, Sept. 8, 2023 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinic...
2023-09-08 10:45
2700
Australian Patient Advocacy Organization Named a Recipient of PTC Therapeutics' 2023 STRIVE™ Award for Duchenne Muscular Dystrophy
- Grant funding will support Save our Sons Duchenne Foundation in developing a digital health app - SYDNEY, Sept. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that an Australian patient advocacy organization is one of the two recipients of the company's 2023 STRI...
2023-09-07 20:00
2244
Teikoku Pharma USA announces positive topline results from Phase 2 clinical trial of TPU-006, non- opioid pain management patch in Abdominoplasty Surgery.
SAN JOSE, Sept. 6, 2023 /PRNewswire/ -- Teikoku Pharma USA, a global pharmaceutical company, today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 4-day dexmedetomidine transdermal patch for Post Surgical Pain. The double-blind, placebo-controlled, single-...
2023-09-06 20:06
2398
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is strongly associated with BRII-179 treatment and correlates with the increased rate of HBsAg loss Saf...
2023-09-06 18:45
3430
Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM
MELBOURNE, Australia, Sept. 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company's theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held inVienna from 9...
2023-09-06 14:18
2387
MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study
GENEVA, Sept. 6, 2023 /PRNewswire/ -- The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which is where ...
2023-09-06 08:00
2417
MALAYSIA HEALTHCARE TRAVEL COUNCIL SELECTS MAYO CLINIC TO PROVIDE STRATEGIC COUNSEL TO FURTHER ADVANCE MEDICAL EXCELLENCE IN MALAYSIA
PUTRAJAYA, Malaysia, Sept. 5, 2023 /PRNewswire/ -- Malaysia Healthcare Travel
Council (MHTC), an agency established under the purview of Ministry of Health
Malaysia, has officially announced the successful establishment of a Memorandum
of Understanding (MoU) with US-basedMayo Clinic
2023-09-05 22:37
2753
YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference
GAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious di...
2023-09-05 20:30
2084
ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001
* Provides clinical validation for ACM Biolab's Tunable Platform ("ATP™"), ACM Biolab's proprietary polymer-based delivery platform * ACM-001 was well tolerated at the recommended dose levels with no serious adverse events and encouraging early immunogenicity data * ACM is in partnering d...
2023-09-05 14:00
2300
Seegene Unveils 'Open Innovation Program Powered by Seegene' in Partnership with Springer Nature
* The program is a part of the Seegene OneSystemTM business aimed at creating a 'world free from all diseases' * Collaborating with clinical researchers worldwide, Seegene will share its technologies and enable researchers to develop syndromic qPCR assays SEOUL, South Korea, Sept. 4, 2023 /PR...
2023-09-04 21:00
3107
National University Health System Launches World's First Public Hospital's Healthy Longevity Clinic at Alexandra Hospital
SINGAPORE, Sept. 2, 2023 /PRNewswire/ -- The National University Health System
(NUHS), NUS Yong Loo Lin School of Medicine andAlexandra Hospital (AH
2023-09-02 13:00
4234
Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors
* Six cohorts, totaling 50 late-stage cancer patients, received STP707 four times monthly by intravenous infusion at escalating dosages. * All cohorts demonstrated a strong safety profile with no dose-limiting toxicity noted for any dosing cohort and the treated patients exhibited encouraging...
2023-08-31 11:30
5572
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Philips Evnia x SEGA: Elevating Immersion for YAKUZA KIWAMI 3 & DARK TIES | Unveiling the 27M2N6501L QD-OLED Monitor - Where Speed Meets Spectacle
[Picked up by 260 media titles]
2026-02-12 15:58
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
8324
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7498
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
7065
